Categories Health Care, U.S. Markets News

Marinus Pharmaceuticals (MRNS) surges on positive data from Ganaxolone trial

Shares of Marinus Pharmaceuticals (MRNS) jumped after the pharma company reported positive data from the Phase 2 ganaxolone clinical trial in women with postpartum depression (PPD). The announcement excited the investors and sent the stock upwards by 18% in the pre-market trading session. However, the stock lost the initial momentum and opened up 10% when it started trading in today’s regular session.

Marinus stated that ganaxolone, its clinical stage drug, was safe and well-tolerated in all dose groups during the trial.  The company added that there were no serious adverse events reported and no discontinuations due to a treatment-related adverse event.

Based on the clinical results, Marinus plans to advance the studies into the next phase of development to evaluate ganaxolone IV and oral dose regimens. The company also expects to present the data from these studies in 1H19.

Postpartum depression is a mood disorder that affects about 15% of women within the first year following childbirth. Common symptoms include feelings of extreme sadness, hopelessness, suicidal ideation, anxiety and fatigue. So far there are no approved treatments for PPD, but the most common treatments are psychotherapy and antidepressants.

Last Tuesday, the Radnor, Pennsylvania-based pharma company, presented data from its ganaxolone Phase 2 clinical trial for the treatment of pediatric genetic epilepsies at the American Epilepsy Society (AES) Annual Meeting. Marinus stated that ganaxolone showed sustained, long-term effectiveness in treating children with CDD, a refractory form of pediatric epilepsy.

Proteostasis Therapeutics stock skyrockets on positive trial results

MRNS stock had dropped 25% in the past three months and 40% in the past one year. The stock closed down 2.64% at $5.17 on Friday.

 

We’re on Flipboard! Follow us to receive the latest stock market, earnings and financial news at your fingertips

Most Popular

Earnings Preview: Home Depot’s Q3 report likely to reflect weak consumer demand

The US housing industry has been mostly resilient to headwinds like economic uncertainties so far this year. However, housing activity cooled in recent months as high mortgage rates and inflation

Take-Two Interactive (TTWO) will report Q2 2025 earnings this week, a few points to note

Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) stayed red on Monday. The stock has gained 16% over the past three months. The gaming company is set to report its second

Earnings Summary: Highlights of Loews Corporation’s (L) Q3 2024 report

Loews Corporation (NYSE: L), a diversified company with businesses in the insurance, energy, hospitality, and packaging industries, on Monday reported higher revenue and profit for the third quarter of 2024.

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top